Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular risk study

Monte Rosa Therapeutics announced on October 1, 2026 positive results from GFORCE-1, a Phase 1 study of MRT-8102, a study that enrolled 108 obese subjects with elevated CVD risk, randomized to MRT-8102 at once-daily doses of 5 mg, 20 mg, or 40 mg, or to placebo.¹ The trial ran over a four-week treatment regimen, followed by four weeks of safety follow-up,¹ assessing safety and pharmacodynamic markers.

Across all three doses, MRT-8102 drove a median NEK7 reduction of roughly 80 to 90 percent.¹ Several biomarkers linked to atherosclerotic plaque biology dropped toward healthy-volunteer levels: calprotectin, S100A12, and SAA fell by medians of 56%, 46%, and 51%, respectively.¹ Fibrinogen, a thrombogenic factor, dropped by a median of 28% to levels matching healthy volunteers,¹ while IL-6 and hsCRP fell by medians of 54% and 85%, with hsCRP reductions occurring quickly and holding steady at levels seen in healthy volunteers.¹ The company also reported that lipoprotein(a) dropped by a median of 24%, a reduction comparable to PCSK9 inhibitors, without the LDL-C or triglyceride increases seen with IL-6 receptor blockade.¹

On safety, the drug was well tolerated over the eight-week study period, with no serious adverse events and treatment-emergent adverse event rates of 33% for MRT-8102 versus 30% for placebo, with no signal of increased infection risk.¹

Monte Rosa said it plans three Phase 2 studies: GFORCE-2, a Phase 2b trial in stable coronary artery disease, expected to start in H1 2027¹; GEMINI-1 in gout, expected to begin in Q4 2026 or Q1 2027 with initial data in H2 2027¹; and GALAXY-1 in moderate to severe hidradenitis suppurativa, expected in H1 2027.¹